Detalhe da pesquisa
1.
Impairment of SARS-CoV-2 spike glycoprotein maturation and fusion activity by nitazoxanide: an effect independent of spike variants emergence.
Cell Mol Life Sci
; 79(5): 227, 2022 Apr 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35391601
2.
Systemic efficacy on Cryptosporidium parvum infection of aminoxanide (RM-5061), a new amino-acid ester thiazolide prodrug of tizoxanide.
Parasitology
; 148(8): 975-984, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33775260
3.
Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza A viruses in vitro.
Antimicrob Agents Chemother
; 59(2): 1061-9, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25451059
4.
Thiazolides, a new class of antiviral agents effective against rotavirus infection, target viral morphogenesis, inhibiting viroplasm formation.
J Virol
; 87(20): 11096-106, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23926336
5.
Activity of halogeno-thiazolides against Cryptosporidium parvum in experimentally infected immunosuppressed gerbils (Meriones unguiculatus).
Antimicrob Agents Chemother
; 57(6): 2821-3, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23478972
6.
The FDA-approved drug nitazoxanide is a potent inhibitor of human seasonal coronaviruses acting at postentry level: effect on the viral spike glycoprotein.
Front Microbiol
; 14: 1206951, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37705731
7.
Thiazolide Prodrug Esters and Derived Peptides: Synthesis and Activity.
ACS Bio Med Chem Au
; 3(4): 327-334, 2023 Aug 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37599793
8.
A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19.
EClinicalMedicine
; 45: 101310, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35237748
9.
The oral drug nitazoxanide restricts SARS-CoV-2 infection and attenuates disease pathogenesis in Syrian hamsters.
bioRxiv
; 2022 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35169796
10.
The Modulation of Cholesterol Metabolism Is Involved in the Antiviral Effect of Nitazoxanide.
Infect Dis Rep
; 13(3): 636-644, 2021 Jul 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34287319
11.
Synthesis, antiviral activity, preliminary pharmacokinetics and structural parameters of thiazolide amine salts.
Future Med Chem
; 13(20): 1731-1741, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34402654
12.
Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level.
J Biol Chem
; 284(43): 29798-808, 2009 Oct 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-19638339
13.
Evaluation of new thiazolide/thiadiazolide derivatives reveals nitro group-independent efficacy against in vitro development of Cryptosporidium parvum.
Antimicrob Agents Chemother
; 54(3): 1315-8, 2010 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-20047919
14.
Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin.
Gastroenterology
; 136(3): 856-62, 2009 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19135998
15.
The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation.
Gastroenterology
; 137(5): 1827-35, 2009 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-19664635
16.
Treatment of chronic hepatitis C using a 4-week lead-in with nitazoxanide before peginterferon plus nitazoxanide.
J Clin Gastroenterol
; 44(7): 504-9, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20048684
17.
Cryptosporidium and Giardia: treatment options and prospects for new drugs.
Exp Parasitol
; 124(1): 45-53, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19632225
18.
Host-targeted nitazoxanide has a high barrier to resistance but does not reduce the emergence or proliferation of oseltamivir-resistant influenza viruses in vitro or in vivo when used in combination with oseltamivir.
Antiviral Res
; 180: 104851, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32544408
19.
Prophylaxis of ferrets with nitazoxanide and oseltamivir combinations is more effective at reducing the impact of influenza a virus infection compared to oseltamivir monotherapy.
Antiviral Res
; 176: 104751, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32088248
20.
Viral burden, inflammatory milieu and CD8+ T-cell responses to influenza virus in a second-generation thiazolide (RM-5061) and oseltamivir combination therapy study.
Influenza Other Respir Viruses
; 14(6): 678-687, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32588557